Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422] (ab189892)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR18422] to ENO1 + ENO2 + ENO3
- Suitable for: WB
- Reacts with: Mouse, Rat, Human, Recombinant fragment
Overview
-
Product name
Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422]
See all ENO1 + ENO2 + ENO3 primary antibodies -
Description
Rabbit monoclonal [EPR18422] to ENO1 + ENO2 + ENO3 -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species WB MouseRatHumanRecombinant fragment -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human ENO1 full length recombinant protein, Human ENO2 full length recombinant protein, Human ENO3 full length recombinant protein, Human fetal liver lysate, Human fetal heart lysate, Human fetal kidney lysate, Human fetal spleen lysate, Mouse brain lysate, Mouse heart lysate, Mouse kidney lysate, Mouse spleen lysate, Rat brain lysate, Rat heart lysate, Rat spleen lysate, HeLa, Jurkat MCF7 , A431, C6, Raw264.7 and NIH/3T3 whole cell lysates
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR18422 -
Isotype
IgG -
Research areas
Images
-
All lanes : Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422] (ab189892) at 1/5000 dilution
Lane 1 : Human ENO1 full length recombinant protein
Lane 2 : Human ENO2 full length recombinant protein
Lane 3 : Human ENO3 full length recombinant protein
Lysates/proteins at 0.02 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 47 kDa
Observed band size: 47 kDa
Exposure time: 5 secondsBlocking and diluting buffer 5% NFDM /TBST.
Human ENO1 full length recombinant protein (Cat#:ab89248) containing aa1-434.
Human ENO2 full length recombinant protein containing aa1-434 with a His-Tag®.
Human ENO3 full length recombinant protein (Cat#:ab113127) containing aa1-434 with a His-Tag®.Human ENO2 full length recombinant protein was made in-house.
-
All lanes : Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422] (ab189892) at 1/5000 dilution
Lane 1 : Human fetal liver lysate
Lane 2 : Human fetal heart lysate
Lane 3 : Human fetal kidney lysate
Lane 4 : Human fetal spleen lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
Developed using the ECL technique.
Predicted band size: 47 kDa
Observed band size: 47 kDa
Exposure time: 5 secondsBlocking and diluting buffer 5% NFDM /TBST.
Exposure time - Lane 1,2 and 3:5 seconds;
Lane 4: 30 seconds -
All lanes : Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422] (ab189892) at 1/5000 dilution
Lane 1 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 2 : Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate
Lane 3 : MCF7 (Human breast adenocarcinoma cell line) whole cell lysate
Lane 4 : A431 (Human epidermoid carcinoma cell line) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 47 kDa
Observed band size: 47 kDa
Exposure time: 3 secondsBlocking and diluting buffer was 5% NFDM /TBST.
-
Lanes 1-7 : Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422] (ab189892) at 1/5000 dilution
Lanes 8-10 : Anti-ENO1 + ENO2 + ENO3 antibody [EPR18422] (ab189892) at 1/1000 dilution
Lane 1 : Mouse brain lysate
Lane 2 : Mouse heart lysate
Lane 3 : Mouse kidney lysate
Lane 4 : Mouse spleen lysate
Lane 5 : Rat brain lysate
Lane 6 : Rat heart lysate
Lane 7 : Rat spleen lysate
Lane 8 : C6 (Rat glial tumor cell line) whole cell lysate
Lane 9 : Raw264.7 (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
Lane 10 : NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 47 kDa
Observed band size: 47 kDa
Exposure time: 1 secondBlocking and diluting buffer was 5% NFDM /TBST.
Exposure time - Lane 1-4 and 8-10: 1 second;
Lane 5-7: 3 seconds; -